Bal Pharma Ltd.
NSE: BALPHARMA | BSE: 524824
₹87.79
₹2.75
(3.23%)
As on 09-Jun-2026IST
Market cap
₹139 Cr
Revenue (TTM)
₹312 Cr
P/E Ratio
22.1
P/B Ratio
1.7
Div. Yield
1.4 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹6 Cr
-
ROE
9.7 %
-
ROCE
10.1 %
-
Industry P/E
34.34
-
EV/EBITDA
8.6
-
Debt to Equity
0.4
-
Book Value
₹51.6
-
EPS
₹3.9
-
Face value
10
-
Shares outstanding
15,924,872
10 Years Aggregate
CFO
₹109.26 Cr
EBITDA
₹204.28 Cr
Net Profit
₹17.22 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bal Pharma
| 19.7 | 9.5 | 21.1 | -12.6 | -0.4 | -2.5 | -0.2 |
|
BSE Healthcare
| 8.7 | 1.4 | 8.4 | 9.2 | 24.9 | 13.5 | 12.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Bal Pharma
| -41.7 | 22.0 | 9.8 | -13.9 | 88.3 | 33.5 | -47.9 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bal Pharma
|
87.8 | 138.7 | 311.7 | 6.3 | 6.7 | 7.8 | 22.1 | 1.7 |
| 3,017.2 | 37,632.5 | 5,452.9 | 1,056.0 | 22.4 | 23.9 | 35.6 | 8.3 | |
| 8,453.0 | 21,143.6 | 2,275.6 | 187.5 | 10.3 | 22.9 | 112.8 | 24.2 | |
| 2,255.2 | 17,160.4 | 2,187.2 | 649.7 | 31.5 | 19 | 26.8 | 4.8 | |
| 1,373.7 | 19,020.4 | 3,129.4 | 647.4 | 26.9 | 18.1 | 30.7 | 4.9 | |
| 2,210.2 | 35,481.1 | 4,147.8 | 709.5 | 22.3 | 19.1 | 50 | 8.5 | |
| 4,592.5 | 20,980.8 | 2,519.7 | 722.4 | 33.6 | 18.8 | 29 | 5.0 | |
| 6,212.5 | 10,324.8 | 1,408.0 | 326.9 | 30.8 | 57.1 | 31.6 | 19.7 | |
| 569.2 | 11,088.5 | 1,538.1 | 226.2 | 20.4 | 9 | 45.6 | 4.3 | |
| 1,017.0 | 9,381.3 | 4,858.7 | 574.1 | 14.9 | 19.7 | 16.9 | 3.0 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Bal Pharma
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products,... intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; herbal liver protective and antioxidant; and cardiac care products under the Secremet and Servace brands. In addition, the company offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment, etc.; and various formulations, including tablets, capsules, syrups, suspensions, ophthalmic, creams, and ointments. Further, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to approximately 30 countries. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India. Read more
-
Incorporated
1987
-
Chairman
--
-
Managing Director
Shailesh Siroya
-
Headquarters
Bengaluru, Karnataka
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Bal Pharma
What is the current share price of Bal Pharma Ltd Today?
The share price of Bal Pharma Ltd is ₹87.79 (NSE) and ₹86.75 (BSE) as of 09-Jun-2026 IST. Bal Pharma Ltd has given a return of -0.4% in the last 3 years.
What is the current PB & PE ratio of Bal Pharma Ltd?
The P/E ratio of Bal Pharma Ltd is 22.07 times as on 09-Jun-2026, a 36 discount to its peers’ median range of 34.34 times.
The P/B ratio of Bal Pharma Ltd is 1.69 times as on 09-Jun-2026, a 63 discount to its peers’ median range of 4.63 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
18.35
|
1.71
|
|
2024
|
19.51
|
2.00
|
|
2023
|
40.83
|
1.65
|
|
2022
|
28.49
|
2.77
|
|
2021
|
16.80
|
1.51
|
What is the 52 Week High and Low of Bal Pharma Ltd?
The 52-week high and low of Bal Pharma Ltd are Rs 111.18 and Rs 60.00 as of 09-Jun-2026.
What is the market cap of Bal Pharma Ltd?
Bal Pharma Ltd has a market capitalisation of ₹ 139 Cr as on 09-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Bal Pharma Ltd?
Before investing in Bal Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.